Shutterstock.com
NHS prescriptions for Mounjaro (tirzepatide; Eli Lilly) will be reimbursed at the new higher list prices, following an agreement between Community Pharmacy England (CPE) and the Department of Health and Social Care (DHSC).
The agreement, announced on 27 August 2025, covers branded and generically written NHS prescriptions for all strengths of Mounjaro dispensed from 1 September 2025, which ensures that pharmacy owners will not be dispensing at a loss.
This follows Lilly’s decision to increase UK list prices for the weight-loss medicine from 1 September 2025 to address “pricing inconsistencies” compared to other developed countries, including in Europe.
Currently, pharmacies pay £92–122 for the drug; however, from 1 September 2025, cost prices for Mounjaro rise to £133 for the 2.5mg dose and £330 for the 12.5mg and 15.0mg doses.
CPE stressed that the new reimbursement rates apply to September 2025 prescriptions, but the updated figures will not appear in the Drug Tariff until October 2025.
In parallel, Lily has said it has “reached an agreement with the NHS to ensure continued supply and patient access”.
While this agreement provides certainty about NHS dispensing of the medicine, the reimbursement will not cover pharmacies providing the drug via private services.
CPE said it “understands there are growing concerns regarding Mounjaro pricing and supply arrangements for private services offered by many pharmacies”.
However, The Pharmaceutical Journal has been told that Lilly has invited pharmacies to complete a commercial agreement with the manufacturer for supply of Mounjaro that will enable pharmacies to claim back a rebate — the value of which is as yet unconfirmed — so that they can reduce the cost to patients.
Lilly also confirmed that pharmacies have been offered commercial terms but would not give more detail.
